Cargando…
Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
BACKGROUND: Mycobacterium tuberculosis(MTB) remains a major public health problem worldwide, and emergence of drug-resistant TB has become a significant obstacle to effective TB control. However, the rate of MTB and rifampicin resistant-MTB (RR-MTB) in the Nepalese setting has not been studied exten...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445509/ https://www.ncbi.nlm.nih.gov/pubmed/32903905 http://dx.doi.org/10.2147/IDR.S263795 |
_version_ | 1783574003310395392 |
---|---|
author | Sah, Shiv Kumar Bhattarai, Pramod Raj Shrestha, Anjana Dhami, Deepak guruwacharya, Deepa Shrestha, Renu |
author_facet | Sah, Shiv Kumar Bhattarai, Pramod Raj Shrestha, Anjana Dhami, Deepak guruwacharya, Deepa Shrestha, Renu |
author_sort | Sah, Shiv Kumar |
collection | PubMed |
description | BACKGROUND: Mycobacterium tuberculosis(MTB) remains a major public health problem worldwide, and emergence of drug-resistant TB has become a significant obstacle to effective TB control. However, the rate of MTB and rifampicin resistant-MTB (RR-MTB) in the Nepalese setting has not been studied extensively. Therefore, the present study aims to assess the rate of MTB and RR-MTB and further determine the factors associated with it. METHODS: A retrospective cross-sectional study, among national representative data of 990 consecutive presumptive TB resister of patients subjected to the GeneXpert test that presented to the tuberculosis referral hospital, was conducted over a one year period from February 2018 to January 2019. Significance for the difference for categorical data was performed by Chi-square test and factors associated with MTB and RR-MTB were assessed using binary logistic regression yielding OR with 95%CI. RESULTS: Of total 990 presumptive tuberculosis analyzed cases, median ages of the patients were 39±19.09 years and two-thirds of the patients were male 653 (66.0%). The estimated prevalence of MTB in presumptive TB patients was 13.8% (95%CI: 11.88%–16.16%), and risk for MTB was significantly associated with previously treated patients: OR: 10.4 (P<0.001). The estimated prevalence of RR-MTB in MTB confirmed patients was 10.2% (4.97%–15.1%). Our study confirmed no association of RR-TB with age, sex, ethnicity, geographical diversity and previous history of treatment failure (P>0.05). CONCLUSION: The overall prevalence of MTB and RR-MTB was high in Nepalese study population, and that being previously treated with anti-TB drug remained significant predictors for MTB; proactive measures are urgently needed to address the challenge of prompt diagnosis, early management and improved monitoring of treatment to limit the emergence drug-resistant MTB strains in the community. |
format | Online Article Text |
id | pubmed-7445509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-74455092020-09-04 Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal Sah, Shiv Kumar Bhattarai, Pramod Raj Shrestha, Anjana Dhami, Deepak guruwacharya, Deepa Shrestha, Renu Infect Drug Resist Original Research BACKGROUND: Mycobacterium tuberculosis(MTB) remains a major public health problem worldwide, and emergence of drug-resistant TB has become a significant obstacle to effective TB control. However, the rate of MTB and rifampicin resistant-MTB (RR-MTB) in the Nepalese setting has not been studied extensively. Therefore, the present study aims to assess the rate of MTB and RR-MTB and further determine the factors associated with it. METHODS: A retrospective cross-sectional study, among national representative data of 990 consecutive presumptive TB resister of patients subjected to the GeneXpert test that presented to the tuberculosis referral hospital, was conducted over a one year period from February 2018 to January 2019. Significance for the difference for categorical data was performed by Chi-square test and factors associated with MTB and RR-MTB were assessed using binary logistic regression yielding OR with 95%CI. RESULTS: Of total 990 presumptive tuberculosis analyzed cases, median ages of the patients were 39±19.09 years and two-thirds of the patients were male 653 (66.0%). The estimated prevalence of MTB in presumptive TB patients was 13.8% (95%CI: 11.88%–16.16%), and risk for MTB was significantly associated with previously treated patients: OR: 10.4 (P<0.001). The estimated prevalence of RR-MTB in MTB confirmed patients was 10.2% (4.97%–15.1%). Our study confirmed no association of RR-TB with age, sex, ethnicity, geographical diversity and previous history of treatment failure (P>0.05). CONCLUSION: The overall prevalence of MTB and RR-MTB was high in Nepalese study population, and that being previously treated with anti-TB drug remained significant predictors for MTB; proactive measures are urgently needed to address the challenge of prompt diagnosis, early management and improved monitoring of treatment to limit the emergence drug-resistant MTB strains in the community. Dove 2020-08-20 /pmc/articles/PMC7445509/ /pubmed/32903905 http://dx.doi.org/10.2147/IDR.S263795 Text en © 2020 Sah et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sah, Shiv Kumar Bhattarai, Pramod Raj Shrestha, Anjana Dhami, Deepak guruwacharya, Deepa Shrestha, Renu Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal |
title | Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal |
title_full | Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal |
title_fullStr | Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal |
title_full_unstemmed | Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal |
title_short | Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal |
title_sort | rifampicin-resistant mycobacterium tuberculosis by genexpert mtb/rif and associated factors among presumptive pulmonary tuberculosis patients in nepal |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445509/ https://www.ncbi.nlm.nih.gov/pubmed/32903905 http://dx.doi.org/10.2147/IDR.S263795 |
work_keys_str_mv | AT sahshivkumar rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal AT bhattaraipramodraj rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal AT shresthaanjana rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal AT dhamideepak rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal AT guruwacharyadeepa rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal AT shrestharenu rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal |